Ironwood Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Ironwood Pharmaceuticals

07/05/2025 14:32

Ironwood Pharmaceuticals Inc IRWD.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of six analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -12 cents to 3 cents per share.

Revenue fell 45.1% to $41.14 million from a year ago; analysts expected $45.98 million.

Ironwood Pharmaceuticals Inc's reported EPS for the quarter was a loss of 23 cents​.

The company reported a quarterly loss of $37.39 million.

Ironwood Pharmaceuticals Inc shares had fallen by 36.9% this quarter and lost 79.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 370.6% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Ironwood Pharmaceuticals Inc is $1.05

This summary was machine generated from LSEG data May 7 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.05
-0.14
Missed
Dec. 31 2024
0.08
0.02
Missed
Sep. 30 2024
0.08
0.02
Missed
Jun. 30 2024
0.15
0.00
Missed